0001437749-17-016781.txt : 20171004 0001437749-17-016781.hdr.sgml : 20171004 20171004163014 ACCESSION NUMBER: 0001437749-17-016781 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171002 FILED AS OF DATE: 20171004 DATE AS OF CHANGE: 20171004 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wrighton-Smith Peter CENTRAL INDEX KEY: 0001592286 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36200 FILM NUMBER: 171121986 MAIL ADDRESS: STREET 1: C/O OXFORD IMMUNOTEC GLOBAL PLC STREET 2: 94C INNOVATION DRIVE CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oxford Immunotec Global PLC CENTRAL INDEX KEY: 0001586049 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ BUSINESS PHONE: 44 01235 442780 MAIL ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ 4 1 rdgdoc.xml FORM 4 X0306 4 2017-10-02 0001586049 Oxford Immunotec Global PLC OXFD 0001592286 Wrighton-Smith Peter C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE X0 OX14 4RZ UNITED KINGDOM 1 1 Chief Executive Officer Ordinary Shares 2017-10-02 4 M 0 55000 0.81 A 516668 D Ordinary Shares 2017-10-02 4 S 0 55000 16.7806 D 461668 D Stock Option (Right to Buy) 0.81 2017-10-02 4 M 0 55000 0 D 2022-12-31 Ordinary Shares 55000 94273 D The original exercise price of these options was priced in GBP at GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended. The price reported for the sales on October 2, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.75 to $16.9425 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016. /s/ Elizabeth M. Keiley, as Attorney-in-Fact for Peter Wrighton-Smith 2017-10-04